JAMA Clinical Reviews JAMA Editors' Choice 2025: Clinical Reviews Podcasts
Dec 30, 2025
Discover the latest in obesity treatments with insights on incretin-based medications, showcasing impressive weight loss stats. Gastrointestinal side effects are discussed alongside dietary tips to enhance medication adherence. Hypothyroidism's risk factors and prevalence are explored, emphasizing tailored levothyroxine dosing. Dive into diabetes care as experts dissect evolving treatment options and screening guidelines for better outcomes. This informative discussion promises to keep healthcare professionals updated and engaged.
AI Snips
Chapters
Transcript
Episode notes
High Efficacy, High GI Burden
- Incretin-based obesity drugs produce unprecedented weight loss, often 15–20% or more.
- GI adverse events occur in about 30–40% and are the main limitation to adherence.
Counsel And Restart Incretin Therapy Carefully
- Counsel patients on diet and dosing before starting incretin obesity medications to reduce GI side effects.
- Restart missed doses at a lower dose and re-escalate slowly to avoid severe nausea or dehydration.
Practical Dietary Steps To Reduce GI Symptoms
- Advise dietary strategies like smaller meals, fewer fatty foods, and avoiding alcohol or carbonated drinks to lessen GI symptoms.
- Emphasize regular meal timing and meal planning to improve tolerability during dose escalation.